In the Press
February 28, 2022

Pharma Dealmaking Hit by Greater Scrutiny of Prices and Competition (Financial Times)

In March last year, the Federal Trade Commission (FTC) joined with its EU, UK and Canadian counterparts to rethink their approach to M&A by “Big Pharma”. Arman Oruc, partner in the Antitrust and Competition practice at Goodwin, says the working group is still consulting. Read the Financial Times article here.